Metastatic potential and prognostic significance of SOX2: A meta-analysis

Table 3 Subgroup analysis of the association between SOX2 expression (high vs low) and LMN and DM

Variable		LNM								DM
		Studies		Model (I2%)		OR (95%CI)		P-value		Studies		Model (I2%)		OR (95%CI)		P-value
Sample size
< 150	13		R (83)		1.85 (0.96-3.56)		0.06		12		F (47)		2.16 (1.61-2.91)		< 0.0001
≥ 150	5		R (85)		0.93 (0.43-2.01)		0.11		1		N/A		0.24 (0.05-1.15)		0.007
Cancer type
Head and neck	6		R (88)		1.89 (0.72-4.96)		0.19		7		F (39)		2.46 (1.63-3.72)		< 0.0001
Esophagus	3		R (79)		0.98 (0.24-4.04)		0.98		1		N/A		0.56 (0.09-3.57)		0.54
Cervix	-		-		-		-		1		N/A		3.12 (0.99-9.82)		0.05
Stomach	4		R (85)		0.68 (0.21-2.24)		0.53		2		R (56)		0.56 (0.16-1.96)		0.36
Breast	2		F (0)		2.87 (1.50-5.50)		0.002		-		-		-		-
Liver	1		N/A		1.68 (0.39-7.32)		0.49		1		N/A		4.80 (1.56-14.76)		0.006
Lung	1		N/A		1.74 (1.02-2.89)		0.04		-		-		-		-
Colon	1		N/A		4.15 (1.43-12.09)		0.009		1		N/A		3.04 (1.15-8.04)		0.03
Quality score
≥ 7	12		R (88)		1.64 (0.82-3.27)		0.16		7		R (69)		2.23 (1.04-4.77)		0.04
< 7	6		R (79)		1.38 (0.60-3.18)		0.45		6		F (35)		1.71 (0.89-3.27)		0.11

DM: Distant metastasis; F: Fixed effects model; LNM: Lymph node metastasis; OR: Odds ratio; R: Random effects model.